← Leaderboards
J. Victor Garcia-Martinez
University Of Texas Sw Med Ctr/Dallas
$43,335,545
Attributed
$49,963,565
Total exposure
30
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,759,446 · 31
By mechanism
R01$36,926,751 · 13
U19$4,461,869 · 3
P01$3,949,065 · 3
R33$2,365,214 · 2
R21$1,861,358 · 5
R56$1,354,581 · 2
Top collaborators
- Angela Raquel Wahl6 shared
- Bryan R. Cullen5 shared
- Ryan Balfour Sartor5 shared
- Ronald I Swanstrom5 shared
- Edward P Browne3 shared
- Susana T Valente3 shared
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- Michael J Gale$70,921,035
- David M. Margolis$89,256,801
- William M Lee$28,967,272
- Preet M. Chaudhary$12,007,840
- W Matthew Petroll$12,265,086
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsCellsIn VivoVirusInfectionAnimal ModelViralHiv-1LaboratoriesPlasmaPreventEvaluationGrantTissuesMouse ModelTransmission ProcessInnovationBone MarrowCd4 Positive T LymphocytesPharmaceutical PreparationsVaginaBaseLiverIn Vivo Model
Grant awards (112)
Novel cell and gene therapy for HIV cure$2,795,881
P01 · FY2025 · AI · contact PI
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice$835,484
R01 · FY2025 · AI
Project 3$750,394
P01 · FY2025 · AI · contact PI
Defining the impact of cannabinoids on the HIV reservoir in humanized mice$738,616
R33 · FY2025 · DA
Administrative Core$402,790
P01 · FY2025 · AI · contact PI
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice$889,277
R01 · FY2024 · AI
Impact of the gastrointestinal microbiome on HIV reservoirs$571,643
R01 · FY2024 · DK
Defining the impact of cannabinoids on the HIV reservoir in humanized mice$519,071
R61 · FY2024 · DA
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice$903,157
R01 · FY2023 · AI
Development of sustained release/long acting products for TB$699,668
R56 · FY2023 · AI · contact PI
Impact of the gastrointestinal microbiome on HIV reservoirs$576,867
R01 · FY2023 · DK
Defining the impact of cannabinoids on the HIV reservoir in humanized mice$534,673
R61 · FY2023 · DA
Impact of the gastrointestinal microbiome on HIV reservoirs$129,965
R01 · FY2023 · DK
Development of sustained release/long acting products for TB$32,981
R56 · FY2023 · AI · contact PI
Impact of the gastrointestinal microbiome on HIV reservoirs$777,023
R01 · FY2022 · DK
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention$413,995
R01 · FY2022 · AI · contact PI
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention$360,519
R01 · FY2022 · AI · contact PI
Impact of the gastrointestinal microbiome on HIV reservoirs$777,023
R01 · FY2021 · DK
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention$774,514
R01 · FY2021 · AI · contact PI
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention$776,006
R01 · FY2020 · AI · contact PI
In Vivo Evaluation of HIV Latency Reversal Strategies$621,932
R56 · FY2020 · AI · contact PI
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention$776,006
R01 · FY2019 · AI · contact PI
Disruption of latent HIV-1 proviruses using CRISPR/Cas endonucleases$732,425
R01 · FY2019 · AI
Role of Myeloid Cells in HIV latency in the Periphery and the CNS$536,555
R01 · FY2019 · MH · contact PI
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention$776,006
R01 · FY2018 · AI · contact PI
Disruption of latent HIV-1 proviruses using CRISPR/Cas endonucleases$741,715
R01 · FY2018 · AI
Role of Myeloid Cells in HIV latency in the Periphery and the CNS$538,470
R01 · FY2018 · MH · contact PI
Plug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ART$453,139
R01 · FY2018 · AI · contact PI
Disruption of latent HIV-1 proviruses using CRISPR/Cas endonucleases$735,615
R01 · FY2017 · AI
Role of Myeloid Cells in HIV latency in the Periphery and the CNS$536,555
R01 · FY2017 · MH · contact PI
Plug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ART$487,499
R01 · FY2017 · AI · contact PI
Disruption of latent HIV-1 proviruses using CRISPR/Cas endonucleases$712,690
R01 · FY2016 · AI
Prevention of HIV Acquisition by Long-acting Antiretroviral PrEP$635,465
R01 · FY2016 · AI · contact PI
Role of Myeloid Cells in HIV latency in the Periphery and the CNS$536,555
R01 · FY2016 · MH · contact PI
Plug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ART$521,436
R01 · FY2016 · AI · contact PI
BLT Model of latency and eradication$795,451
U19 · FY2015 · AI · contact PI
Prevention of HIV Acquisition by Long-acting Antiretroviral PrEP$633,037
R01 · FY2015 · AI · contact PI
Role of Myeloid Cells in HIV latency in the Periphery and the CNS$595,496
R01 · FY2015 · MH · contact PI
Plug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ART$487,157
R01 · FY2015 · AI · contact PI
Disruption of latent HIV-1 proviruses using CRISPR/Cas endonucleases$405,406
R01 · FY2015 · AI
Plug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ART$46,649
R01 · FY2015 · AI · contact PI
Next Generation Pre-exposure Prophylaxis$705,599
R01 · FY2014 · AI · contact PI
Prevention of HIV Acquisition by Long-acting Antiretroviral PrEP$633,949
R01 · FY2014 · AI · contact PI
Plug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ART$486,481
R01 · FY2014 · AI · contact PI
BLT Model of latency and eradication$362,228
U19 · FY2014 · AI · contact PI
Next Generation Pre-exposure Prophylaxis$1,053,496
R01 · FY2013 · AI · contact PI
BLT Model of latency and eradication$798,736
U19 · FY2013 · AI · contact PI
Prevention of HIV Acquisition by Long-acting Antiretroviral PrEP$595,276
R01 · FY2013 · AI · contact PI
Topical Antiretrovirals to Prevent Rectal HIV Infection$306,786
U19 · FY2013 · AI · contact PI
Next Generation Pre-exposure Prophylaxis$990,531
R01 · FY2012 · AI · contact PI
BLT Model of latency and eradication$501,533
U19 · FY2012 · AI · contact PI
Topical Antiretrovirals to Prevent Rectal HIV Infection$346,836
U19 · FY2012 · AI · contact PI
Towards therapy-induced lethal HIV mutagenesis$247,830
R21 · FY2012 · AI · contact PI
Towards therapy-induced lethal HIV mutagenesis$12,333
R21 · FY2012 · AI · contact PI
Next Generation Pre-exposure Prophylaxis$732,433
R01 · FY2011 · AI · contact PI
Topical Antiretrovirals to Prevent Rectal HIV Infection$365,160
U19 · FY2011 · AI · contact PI
BLT Model of latency and eradication$325,694
U19 · FY2011 · AI · contact PI
Towards therapy-induced lethal HIV mutagenesis$235,215
R21 · FY2011 · AI · contact PI
Vaginal/Rectal HIV Transmission Model$564,712
R01 · FY2010 · AI · contact PI
Implementation of a vaginal/rectal HIV transmission to model to evaluate microbic$494,098
R33 · FY2010 · AI · contact PI
Nef Function$392,657
R01 · FY2010 · AI · contact PI
Implementation of a vaginal/rectal HIV transmission to model to evaluate microbic$370,000
R33 · FY2010 · AI · contact PI
Topical Antiretrovirals to Prevent Rectal HIV Infection$335,505
U19 · FY2010 · AI · contact PI
Vaginal/Rectal HIV Transmission Model$553,804
R01 · FY2009 · AI · contact PI
Nef Function$385,074
R01 · FY2009 · AI · contact PI
Implementation of a vaginal/rectal HIV transmission to model to evaluate microbic$370,000
R33 · FY2009 · AI · contact PI
Topical Antiretrovirals to Prevent Rectal HIV Infection$323,940
U19 · FY2009 · AI · contact PI
Vaginal/Rectal HIV Transmission Model$570,370
R01 · FY2008 · AI · contact PI
Nef Function$396,595
R01 · FY2008 · AI · contact PI
Implementation of a vaginal/rectal HIV transmission to model to evaluate microbic$392,500
R33 · FY2008 · AI · contact PI
Gene Transfer System for AIDS Therapy$169,012
R01 · FY2008 · AI · contact PI
Gene Transfer System for AIDS Therapy$148,342
R01 · FY2008 · AI · contact PI
Nef Function$66,333
R01 · FY2008 · AI · contact PI
Vaginal/Rectal HIV Transmission Model$564,483
R01 · FY2007 · AI · contact PI
Hematopoietic Stem Cell Gene Transfer$422,527
R01 · FY2007 · CA · contact PI
Nef Function$392,500
R01 · FY2007 · AI · contact PI
PRE-CLINICAL EVALUATION OF GENE THERAPY FOR SICKLE CELL DISEASE$352,847
U54 · FY2007 · HL · contact PI
Gene Transfer System for AIDS Therapy$332,812
R01 · FY2007 · AI · contact PI
Regulation of Nef Activities by Phosphorylation$228,671
R21 · FY2007 · AI · contact PI
Implementation of a vaginal/rectal HIV transmission to model to evaluate microbic$218,381
R21 · FY2007 · AI · contact PI
Structural Plasticity of an HIV-1 Nef/Pak-2 Activity Surface$190,559
R21 · FY2007 · AI · contact PI
Infectious Diseases Training Program$113,257
T32 · FY2007 · AI · contact PI
Hematopoietic Stem Cell Gene Transfer$422,472
R01 · FY2006 · CA · contact PI
Gene Transfer System for AIDS Therapy$342,752
R01 · FY2006 · AI · contact PI
Nef Function$342,752
R01 · FY2006 · AI · contact PI
PRE-CLINICAL EVALUATION OF GENE THERAPY FOR SICKLE CELL DISEASE$320,760
U54 · FY2006 · HL · contact PI
Structural Plasticity of an HIV-1 Nef/Pak-2 Activity Surface$235,500
R21 · FY2006 · AI · contact PI
Regulation of Nef Activities by Phosphorylation$196,250
R21 · FY2006 · AI · contact PI
Implementation of a vaginal/rectal HIV transmission to model to evaluate microbic$187,419
R21 · FY2006 · AI · contact PI
Nef Function$123,226
R01 · FY2006 · AI · contact PI
Nef Function$469,128
R01 · FY2005 · AI
Hematopoietic Stem Cell Gene Transfer$420,038
R01 · FY2005 · CA
Gene Transfer System for AIDS Therapy$351,000
R01 · FY2005 · AI
Nef Function$465,960
R01 · FY2004 · AI
Hematopoietic Stem Cell Gene Transfer$407,804
R01 · FY2004 · CA
Gene Transfer System for AIDS Therapy$351,000
R01 · FY2004 · AI
Hematopoietic Stem Cell Gene Transfer$395,930
R01 · FY2003 · CA
Nef Function$351,000
R01 · FY2003 · AI
CELLULAR PROTEINS INVOLVED IN HIV1 TAR RNA FUNCTION$267,225
R01 · FY2003 · AI
Nef Function$99,945
R01 · FY2003 · AI
HEMATOPOIETIC STEM CELL GENE TRANSFER$351,000
R01 · FY2002 · CA
NEF FUNCTION$306,880
R01 · FY2002 · AI
Preclinical Evaluation of Gene Therapy for SCD$295,760
R01 · FY2002 · HL
GENE TRANSFER SYSTEM FOR AIDS THERAPY$273,000
R01 · FY2002 · AI
CELLULAR PROTEINS INVOLVED IN HIV1 TAR RNA FUNCTION$259,442
R01 · FY2002 · AI
HEMATOPOIETIC STEM CELL GENE TRANSFER$351,000
R01 · FY2001 · CA
NEF FUNCTION$297,941
R01 · FY2001 · AI
GENE TRANSFER SYSTEM FOR AIDS THERAPY$273,000
R01 · FY2001 · AI
HEMATOPOIETIC STEM CELL GENE TRANSFER$315,900
R01 · FY2000 · CA
NEF FUNCTION$289,261
R01 · FY2000 · AI
GENE TRANSFER SYSTEM FOR AIDS THERAPY$273,000
R01 · FY2000 · AI
NEF ASSOCIATED KINASE$109,200
R21 · FY2000 · GM